ID
22203
Description
A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD) Medicine: rosiglitazone, Condition: Alzheimer's Disease, Phase: 2, Clinical Study ID: 49653/461, Sponsor: GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1 This form is to be completed in/ after Screening Period 2, 1 Month +/- 3 Days, 6 Months +/- 1 week and 12 Months +/- 1 week.
Lien
https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1
Mots-clés
Versions (1)
- 22/05/2017 22/05/2017 -
Téléchargé le
22 mai 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
FDG Pet Scan Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
FDG Pet Scan Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
Similar models
FDG Pet Scan Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
C0808070 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,2])
C0947611 (UMLS CUI [1,2])
C3174092 (UMLS CUI [1,2])
C0449468 (UMLS CUI [1,2])